Oral Presentation ESA-SRB-NZSE-CaSR 2026 in conjunction with ENSA

A Mosaic PHEX Variant in Hypophosphatemic Rickets: Distinguishing Postzygotic Mutation from Sex Chromosome Aneuploidy (143769)

Wu Tzen Lim 1 2 , Marni Nenke 1 2 , Lesley Rawlings 3 , Amanda Wells 3 , Cassandra Vakulin 3 , Wendy Waters 3 , Sunita De Sousa 2 4 5
  1. Endocrine & metabolic service, Royal Adelaide Hospital , Adelaide
  2. Adelaide Medical School, Adelaide University, Adelaide, SA, Australia
  3. Department of Genetics & Molecular Pathology, SA Pathology, Adelaide, South Australia, Australia
  4. Endocrinology Department, Royal Adelaide Hospital , Adelaide, South Australia
  5. Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, Australia., Adelaide, South Australia, Australia

Hereditary hypophosphatemic rickets, most commonly caused by X-linked dominant PHEX variants, leads to hypophosphatemia and bone mineralization defects. We identified a novel mosaic nonsense variant in the PHEX gene on the X chromosome by next-generation sequencing-c.1971C > A, p.(Tyr657X)--in a man with clinical features of hypophosphatemic rickets. As the variant was only found in 67% of DNA reads, we considered the possibility of sex chromosome aneuploidy (e.g. a 48,XXXY sex chromosome complement with an unaffected X chromosome i.e. variant on 2 of 3 X chromosomes producing a variant allele frequency of approx. 67%) or a postzygotic mutation resulting in the PHEX variant in some but not all cells. His mother was clinically unaffected, and he did not have features of Klinefelter's syndrome, favouring postzygotic mutation over sex chromosome aneuploidy. We excluded sex chromosome aneuploidy through karyotype studies showing a 46,XY status. As the event must therefore be a postzygotic variant to produce the reduced variant allele frequency, his parents are not at risk of having the variant. However, X chromosome postzygotic mutations in men may be inherited by female offspring (depending on the mosaic status of gonadal tissue). The patient's karyotype result was thus integral in the investigation of disease mechanism and in guiding family genetic counselling.

  1. Goji K, Ozaki K, Sadewa AH, Nishio H, Matsuo M (2006) Somatic and germline mosaicism for a mutation of the PHEX gene can lead to genetic transmission of X-linked hypophosphatemic rickets that mimics an autosomal dominant trait. J Clin Endocrinol Metab 91(2):365–370. 10.1210/jc.2005-1776.
  2. Shih NR, Jo OD, Yanagawa N (2002) Effects of PHEX antisense in human osteoblast cells. J Am Soc Nephrol 13(2):394–399. 10.1681/ASN.V132394.
  3. Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 7:287–295.
  4. Stamp TC, Baker LR (1976) Recessive hypophosphatemic rickets, and possible aetiology of the ‘vitamin D-resistant’ syndrome. Arch Dis Child 51(5):360–365. 10.1136/adc.51.5.360.
  5. Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82(2):674–681. 10.1210/jcem.82.2.3765.
  6. Durmaz E, Zou M, Al-Rijjal RA, Baitei EY, Hammami S, Bircan I, Akçurin S, Meyer B, Shi Y (2013) Novel and de novo PHEX mutations in patients with hypophosphatemic rickets. Bone 52(1):286–291. 10.1016/j.bone.2012.10.012.
  7. Zhu X, Li M, Pan H, Bao X, Zhang J, Wu X (2010) Analysis of the parental origin of de novo MECP2 mutations and X chromosome inactivation in 24 sporadic patients with Rett syndrome in China. J Child Neurol 25(7):842–848. 10.1177/0883073809350722.
  8. Clausmeyer S, Hesse V, Clemens C, Engelbach M, Kreuzer M, Becker-Rose P, Spital H, Schulze E, Raue F (2009) Mutational analysis of PHEX gene: novel point mutations and detection of large deletions by MLPA in patients with X-linked hypophosphatemic rickets. Calcif Tissue Int 85(3):211–220. 10.1007/s00223-009-9260-8.
  9. Weng C, Chen J, Sun L, Zhou ZW, Feng X, Sun JH, Lu LP, Yu P, Qi M (2016) A de novo mosaic mutation of PHEX in a boy with hypophosphatemic rickets. J Hum Genet 61(3):223–227. 10.1038/jhg.2015.133.
  10. Yang M, Kim J, Yong A, Jang J, Jeon TY, Cho SY, Jin DK (2018) A novel de novo mosaic mutation in PHEX in a Korean patient with hypophosphatemic rickets. Ann Pediatr Endocrinol Metab 23(4):229–234. 10.6065/apem.2018.23.4.229
  11. Zhang C, Zhao Z, Sun Y, Xu L, JiaJue R, Cui L, Pang Q et al (2019) Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemia. Bone 121:212–220. 10.1016/j.bone.2019.01.021.
  12. Lin Y, Xu J, Li X, Sheng H, Su L, Wu M, Cheng J et al (2020) Novel variants and uncommon cases among southern Chinese children with X-linked hypophosphatemia. J Endocrinol Invest 43:1577–1590. 10.1007/s40618-020-01240-6.
  13. Broseta JJ, Lopez-Romero LC, Ceron JA, Mendizabal S, Hernandez-Jaras J (2020) Mosaicism in 2 cases of X-linked hypophosphatemia. Endocrinol Diabet Nutr (Engl Ed) 67(1):70–71. 10.1016/j.endinu.2019.05.009.
  14. Asano S, Sako S, Funasaki Y, Takeshita Y, Niida Y, Takamura T (2021) A mosaic mutation of phosphate-regulating gene with homologies to endopeptidases on the X chromosome (PHEX) in X-linked hypophosphatemic rickets with mild bone phenotypes. Endocr J 68(9):1135–1141. 10.1507/endocrj.EJ20-0809.
  15. Lin Y, Cai Y, Xu J, Zeng C, Sheng H, Yu Y, Li X, Liu L (2020) "Isolated" germline mosaicism in the phenotypically normal father of a girl with X-linked hypophosphatemic rickets. Eur J Endocrinol 182(1):1–6. 10.1530/EJE-19-0472.
  16. Terracciano A, De Bernardi ML, Novizio R, De Brasi D, Iolascon A, Monica MD, Sacvuzzo F, Serino D et al (2023) A new de novo mosaic mutation of PHEX gene: a case report of a boy with hypophosphatemic rickets. Endocr Metab Immune Disord Drug Targets 23(9):1235–1239. 10.2174/1871530323666230227142202.
  17. Ma XS, Pang Q, Gong Y, Li X, Liu W, Jiang Y, Wang O et al (2024) Identification of rare and novel PHEX variants in X-linked hypophosphatemia. J Clin Endocrinol Metab 109(12):3176–3185. 10.1210/clinem/dgae299.
  18. Wippert PM, Rector M, Kuhn G, Wuertz-Kozak K (2017) Stress and alterations in bones: an interdisciplinary perspective. Front Endocrinol (Lausanne) 8:96. 10.3389/fendo.2017.00096.
  19. Fratzl-Zelman N, Gamsjaeger S, Blouin S, Kocijan R, Plasenzotti P, Rokidi S, Nawrot-Wawrzyniak K, Roetzer K, Uyanik G, Haeusler G, Shane E, Cohen A, Klaushofer K, Paschalis EP, Roschger P, Fratzl P, Zwerina J, Zwettler E (2020) Alterations of bone material properties in adult patients with X-linked hypophosphatemia (XLH). J Struct Biol 211(3):107556. 10.1016/j.jsb.2020.107556.
  20. Nguyen-Khac V, Bonnet-Lebrun A, Skalli W, Adamsbaum C, Linglart A, Wicart P (2023) Changes in adipose bone marrow and bone morphology in X-linked hypophosphatemic rickets. Orthop Traumatol Surg Res 109(3):103529. 10.1016/j.otsr.2023.103529.
  21. Rauch F (2006) Material matters: a mechanostat-based perspective on bone development in osteogenesis imperfecta and hypophosphatemic rickets. J Musculoskelet Neuronal Interact 6(2):142–146.
  22. Martinez RP, Khoury S, Harrell M, Lyles RM, Friedman KW, Harrelson N et al (1985) Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med 313(1):1–6. 10.1056/NEJM198507043130101.
  23. Takeyari S, Yamamoto T, Kinoshita Y, Fukumoto S, Glorieux FH, Michigami T, Hasegawa K (2014) Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome. Bone 67:56–62. 10.1016/j.bone.2014.06.026.
  24. Polisson RP, Martinez S, Khoury M, Harrell RM, Lyles KW, Friedman N, Harrelson JM et al (1985) Calcification of entheses associated with X-linked hypophosphatemic osteomalacia. N Engl J Med 313(1):1–6. 10.1056/NEJM198507043130101.
  25. Che H, Roux C, Etcheto A, Rothenbuhler A, Kamenicky P, Linglart A, Briot K (2016) Impaired quality of life in adults with X-linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol 174(3):325–333. 10.1530/EJE-15-0661.
  26. Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T et al (2018) A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X-linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res 33(8):1383–1393. 10.1002/jbmr.3475.
  27. Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK et al (2021) Burosumab treatment in adults with X-linked hypophosphatemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open 7(3):e001714. 10.1136/rmdopen-2021-001714.
  28. Kamenicky P, Briot K, Brandi ML, Cohen-Solal M, Crowley RK, Keen R, Kolta S et al (2023) Benefit of burosumab in adults with X-linked hypophosphatemia (XLH) is maintained with long-term treatment. RMD Open 9(1):e002676. 10.1136/rmdopen-2022-002676.